Novartis Forecasts 5% Annual Sales Growth
The Swiss drugmaker raised peak sales estimates for several key medicines, projecting steady growth through 2031.
Updated on Nov. 19, 2026 in Healthcare

Novartis expects net sales to grow an average of 5% per year from 2026 to 2031, excluding exchange-rate effects. The company also raised peak annual sales forecasts for Kesimpta, Scemblix, Leqvio and Rhapsido.
Why it matters
The revised outlook signals management confidence in the company's medium-term growth from existing drugs and new launches. It also indicates a planned recovery in profitability over the coming years.
Novartis projects 5% average annual net sales growth from 2026 to 2031, excluding currency effects, with its core operating margin targeted above 40% by 2029. Peak sales forecasts were raised to $8 billion each for Kesimpta and Rhapsido, while nine on-market products could each reach $3 billion to $10 billion annually.
The players
Novartis
A Swiss multinational pharmaceutical company headquartered in Basel, known for a broad portfolio of prescription medicines across cardiovascular, neurology, and immunology.
The details
Novartis attributes expected growth to rising sales of existing drugs and to new products reaching the market. The company said the higher peak forecasts reinforced its confidence in its medium-term outlook, and it sees several billion dollars in additional sales potential from other Rhapsido uses.
Timeline
2026 to 2031: Period over which Novartis projects 5% average annual net sales growth.
2029: Target year for core operating margin to recover above 40%.
Market Landscape
The upward revisions for Kesimpta, Scemblix, and Leqvio update Novartis's earlier peak sales estimates, which had set these products at $6 billion and $4 billion respectively. The changes suggest the company expects its existing portfolio to carry much of its growth into the next decade.
For patients using these medicines, the forecasts point to continued investment in existing treatments rather than immediate changes in pricing or access. Investors tracking the drugmaker can use the 2029 margin target as a benchmark for evaluating future financial results.
The takeaway
Revised peak sales forecasts often signal which products a drugmaker expects to drive its growth over several years. Readers following the pharmaceutical sector can track whether Novartis meets its 2029 margin target to judge the strength of this outlook.
Further reading
Explore more pharmaceutical industry coverage in the Healthcare section.



